Hyman, Phelps & McNamara, P.C.
Washington, District of Columbia Office View all offices
700 Thirteenth Street, N.W., Suite 1200
Washington, District of Columbia
20005-5929
Telephone: 202-737-5600
Fax: 202-737-9329
http://www.hpm.com
Profile Visibility  | | #57 in weekly profile views out of 2,740 law firms in Washington, District of Columbia | | #2,335 in weekly profile views out of 264,196 total law firms Overall |
|
|
Office Hours: Monday: 08:30 AM-06:30 PM
Tuesday: 08:30 AM-06:30 PM
Wednesday: 08:30 AM-06:30 PM
Thursday: 08:30 AM-06:30 PM
Friday: 08:30 AM-06:30 PM
|
|
About this office:
Hyman, Phelps & McNamara, P.C. is a law firm that advises and represents a broad range of clients on legal issues concerning food, drug, medical device and cosmetic law and regulation. To complement its core expertise in FDA matters, the firm also serves its clients in related areas, such as advertising, controlled substance regulation, health care fraud and abuse, reimbursement, pricing laws and government contracts. In 1980, three former U.S. Food and Drug Administration (FDA) lawyers opened the firm in Washington, D.C. to concentrate in this area of the law. Hyman, Phelps & McNamara, P.C. now has one of the most extensive food and drug practices in the United States.
Statement of Practice Summary:
Practice before all Courts, Government Agencies, International Regulatory Authorities involving Foods, Drugs, Cosmetics, Medical Devices, Biologics, Pesticides, Health Care, Controlled Substances and Consumer Products.
Documents by Lawyers at this office | |
FDA’s PLAIR Program Collides With Hatch-WaxmanKurt R. Karst, May 25, 2012
FDA’s recent approval of ANDAs for generic versions of sanofi-aventis’ (“sanofi’s”) blockbuster blood thinner drug PLAVIX (clopidogrel bisulfate) Tablets (approved under NDA No. 020839) upon the May 17, 2012 expiration of a period of pediatric exclusivity associated...
Abbott’s Resolution of Off-Label Allegations Has Familiar and New Elements to ItJames P. Ellison, May 23, 2012
Virtually all of the mainstream and trade press outlets have covered the recent Abbott resolution with the U.S. Department of Justice regarding allegations of off-label promotion of Abbott’s drug Depakote. Undoubtedly, the $1.5B price tag and that coverage have made most readers of this blog...
Initial Decision in POM Wonderful Case - Each Side Can Claim VictoryRiëtte van Laack, May 22, 2012
On May 21, 2012, the FTC posted the 345-page Administrative Law Judge’s ("ALJ’s") Initial Decision in In the Matter of POM Wonderful LLC et al. ("POM") (FTC Docket No. 9344). The ALJ upheld the FTC’s Complaint insofar as the FTC asserted that POM made...
Year Established: 1980